Organon divests JADA system to Laborie in $465m deal
Organon is selling its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical in a deal valued at up to $465m.
The US-based company will receive $440m at the deal’s closing, with additional payments up to $25m, subject to certain 2026 revenue targets being achieved. Around 100 Organon employees are expected to transfer to Laborie as part of the agreement. The transaction is expected to complete by Q1 2026.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Neither Organon nor Laborie immediately responded to Medical Device Network’s request for more details around what the revenue targets would be.
Originally developed by Alydia Health, the JADA system comprises an intrauterine vacuum designed to control and treat abnormal postpartum uterine bleeding or haemorrhage. The device gained US Food and Drug Administration (FDA) clearance in 2020 and was then acquired by Organon for $240m in 2021.
Reflecting on the sale of JADA, Organon’s interim CEO Joseph Morrissey said the deal would improve capacity on Organon’s balance sheet to “be able to pursue other growth opportunities in women’s health biopharma in the future.”
Organon span off from MSD in 2021, inheriting debt of around $9.5bn. According to Organon’s Q2 2025 financials, its debt remains at $8.9bn.
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWhile JADA’s sales grew 40% in 2024 to $61m, it appears evident that alongside paying down the debt on its balance sheet, Organon is choosing to move away from medtech women’s health devices to renew its focus on its women’s health biopharma range. Nexplanon is the company’s top-selling biopharma product, achieving around $179m in revenue in Q2 2025.
The contraceptive implant recently took centre stage in a sales malpractice imbroglio uncovered by Organon’s board in October 2025 that resulted in the company’s CEO Kevin Ali standing down from his position. According to the board’s probe, Organon was conducting “improper” wholesaler sales practices, whereby it encouraged US-based wholesalers to buy more Nexplanon units than they required.
Organon’s stock value dropped 20.9% from $9.16 at market close on 24 October to $7.25 at market open on 27 October following the publication of the probe’s findings. The sales malpractice revelation further doused the company’s stock performance, which has decreased by more than 60% in the past year to a current price per share of $6.61, down from around $17-$18 in November 2024.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Medical Device Network Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!
Nominate NowContent Original Link:
" target="_blank">
